Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score

Evaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score

To determine the influence of maximal androgen blockade (MAB) and non-MAB hormonal therapy with an luteinizing hormone releasing hormone (LHRH) analog on overall survival of prostate cancer patients in the Japan Study Group of Prostate Cancer (J-CaP) registry according to risk, as assessed using the...

Full description

Bibliographic Details
Main Author:	Hideyuki Akaza
Format:	Article
Language:	English
Published:	Elsevier 2013-06-01
Series:	Prostate International
Subjects:	Prostate neoplasms Maximal androgen blockade Overall survival Primary androgen deprivation therapy Risk scoring
Online Access:	http://www.sciencedirect.com/science/article/pii/S2287888215300295

Similar Items

The Influence of Androgen Deprivation Therapy on Prostate Size and Voiding Symptoms in Prostate Cancer Patients in Korea
by: Hoon Choi, et al.
Published: (2016-12-01)

Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer
by: Wook Nam, et al.
Published: (2018-01-01)

Role of maximum androgen blockade in advanced prostate cancer
by: Rajinikanth Ayyathurai, et al.
Published: (2009-01-01)

Maximal androgen blockade for advanced prostate cancer
by: Rajiv Paul Mukha, et al.
Published: (2010-01-01)

Intermittent androgen deprivation therapy: recommendations to improve the management of patients with prostate cancer following the GRADE approach
by: Bonfill X, et al.
Published: (2018-08-01)

Androgen Deprivation Therapy Combined With Particle Therapy for Prostate Cancer: A Systematic Review
by: Stine Elleberg Petersen, et al.
Published: (2021-06-01)

Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy
by: Sun-Ouck Kim, et al.
Published: (2009-04-01)

Prognostic significance of genetic polymorphisms in disease progression and survival in prostate cancer after androgen deprivation therapy
by: Tsung-Yi Huang, et al.
Published: (2015-06-01)

Pretreatment serum albumin/globulin ratio as a prognostic biomarker in metastatic prostate cancer patients treated with maximal androgen blockade
by: Ning Wang, et al.
Published: (2019-01-01)

A Comprehensive Review of Androgen Deprivation Therapy and Immunotherapy on Prostate Cancer
by: ZHU Hui, et al.
Published: (2019-10-01)

Adverse effects of androgen deprivation therapy in prostate cancer: Current management issues
by: Aditya Bagrodia, et al.
Published: (2009-01-01)

Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer
by: Szu-Yuan Wu, et al.
Published: (2020-01-01)

Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer
by: Narita Shintaro, et al.
Published: (2012-01-01)

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
by: Frederico Leal, et al.
Published: (2015-06-01)

<i>NRG1</i> Genetic Variant Influences the Efficacy of Androgen-Deprivation Therapy in Men with Prostate Cancer
by: Shu-Pin Huang, et al.
Published: (2021-05-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer
by: Syed Imran Ali Shah
Published: (2015-01-01)

Androgen deprivation therapy during and after post-prostatectomy radiotherapy in patients with prostate cancer: a case control study
by: Myong Kim, et al.
Published: (2018-03-01)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
by: Satoru Ueno, et al.
Published: (2018-03-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Risk of ischemic stroke in patients with prostate cancer receiving androgen deprivation therapy in Taiwan
by: Kuang-Ming Liao, et al.
Published: (2019-12-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
by: Yong Luo, et al.
Published: (2018-06-01)

Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2021-03-01)

No increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
by: Liu JM, et al.
Published: (2018-09-01)

Cardiometabolic and Skeletal Risk Factors in Black Men with Prostate Cancer Starting Androgen Deprivation Therapy
by: Orvar Gunnarsson, et al.
Published: (2015-04-01)

Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population‐based propensity score matching study
by: Bum Sik Tae, et al.
Published: (2019-08-01)

Radiation therapy and androgen deprivation in the management of high risk prostate cancer
by: Alan Dal Pra, et al.
Published: (2011-04-01)

Development of a nomogram model predicting current bone scan positivity in patients treated with androgen-deprivation therapy for prostate cancer
by: Michael eKattan
Published: (2014-10-01)

Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients
by: Yue Wang, et al.
Published: (2017-01-01)

Impact of neoadjuvant androgen deprivation therapy on magnetic resonance imaging features in prostate cancer before radiotherapy
by: Ulrika Björeland, et al.
Published: (2021-01-01)

Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
by: Heikki Seikkula, et al.
Published: (2020-03-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

COMBINED RADIATION THERAPY FOR PROSTATE CANCER WITH DOSE ESCALATION BRACHYTHERAPY AND ANDROGEN DEPRIVATION
by: Auchynikau V. A., et al.
Published: (2018-09-01)

Asian trends in primary androgen depletion therapy on prostate cancer
by: Hideyuki Akaza
Published: (2013-12-01)

Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility
by: Fernand Labrie
Published: (2004-02-01)

Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer
by: Giovanni Corona, et al.
Published: (2021-07-01)

Orchiectomy versus combined androgen blockade in the management of advanced carcinoma prostate
by: M S Ansari, et al.
Published: (2001-01-01)

Association between Androgen Deprivation Therapy and Risk of Dementia in Men with Prostate Cancer
by: Jui-Ming Liu, et al.
Published: (2021-07-01)

Integrating diet and exercise into care of prostate cancer patients on androgen deprivation therapy
by: Moyad MA, et al.
Published: (2016-08-01)